To Evaluate the Safety of Autologous Tumor-infiltrating Lymphocytes(TILs) for the Treatment of Recurrent Ovarian Cancer

NCT07651124 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

6

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Ovarian Cancer

Interventions

OTHER: autologous tumor-infiltrating lymphocytes

Sponsor

Yong Wha Moon